Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 infection drives a glycan switch of peripheral T cells at diagnosis

Inês Alves, Manuel M. Vicente, Joana Gaifem, Ângela Fernandes, Ana M. Dias, Cláudia S. Rodrigues, José Carlos Oliveira, Nair Seixas, Luis Malheiro, Miguel A. Abreu, Rui Sarmento e Castro, Salomé S. Pinho
doi: https://doi.org/10.1101/2021.02.17.21251918
Inês Alves
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
3Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel M. Vicente
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
4Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joana Gaifem
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ângela Fernandes
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana M. Dias
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cláudia S. Rodrigues
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Carlos Oliveira
5Department of Clinical Pathology, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nair Seixas
6Department of Clinical Pathology, Centro Hospitalar Vila Nova de Gaia/Espinho, 4434-502 Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Malheiro
7Department of Infectious Diseases, Centro Hospitalar Vila Nova de Gaia/Espinho, 4434-502 Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel A. Abreu
4Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
8Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rui Sarmento e Castro
4Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
8Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salomé S. Pinho
1Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal
3Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
4Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: salomep@ipatimup.pt
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. Here, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor, through the up-regulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. These new evidences pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health (i3S) research unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This article was partially funded by the FCT, in collaboration with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, RESEARCH 4 COVID-19_Project #006 granted to the PI Salomé S. Pinho. IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] 25 received funding from the FCT.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants gave informed consent about all clinical procedures and research protocols were approved by the ethics committee of CHUP and CHVNG, Portugal.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵9 Lead Contact

  • Grant Support: The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health (i3S) research unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This article was partially funded by the FCT, in collaboration with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, “RESEARCH 4 COVID-19”_Project #006 granted to the PI Salomé S. Pinho. IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] received funding from the FCT.

Data Availability

Data is not available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 infection drives a glycan switch of peripheral T cells at diagnosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 infection drives a glycan switch of peripheral T cells at diagnosis
Inês Alves, Manuel M. Vicente, Joana Gaifem, Ângela Fernandes, Ana M. Dias, Cláudia S. Rodrigues, José Carlos Oliveira, Nair Seixas, Luis Malheiro, Miguel A. Abreu, Rui Sarmento e Castro, Salomé S. Pinho
medRxiv 2021.02.17.21251918; doi: https://doi.org/10.1101/2021.02.17.21251918
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 infection drives a glycan switch of peripheral T cells at diagnosis
Inês Alves, Manuel M. Vicente, Joana Gaifem, Ângela Fernandes, Ana M. Dias, Cláudia S. Rodrigues, José Carlos Oliveira, Nair Seixas, Luis Malheiro, Miguel A. Abreu, Rui Sarmento e Castro, Salomé S. Pinho
medRxiv 2021.02.17.21251918; doi: https://doi.org/10.1101/2021.02.17.21251918

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10550)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3979)
  • Radiology and Imaging (653)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)